CliffBio
small molecule

VICTRELIS

BOCEPREVIR

Loss of exclusivityNovember 2027latest FDA-listed patent expiry
CompanyMERCK SHARP AND DOHME CORP

Drug detail

Brand nameVICTRELIS
Active ingredientBOCEPREVIR
Strength200MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2011
Marketing statusDISCN

Listed patents

PatentExpiresType
7772178November 2027product
8119602March 2027use U-1233

More from MERCK SHARP AND DOHME CORP

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VICTRELIS patent cliff — loss of exclusivity November 2027 | CliffBio